Early Insulin Therapy Shows Promise for Reducing Cardiovascular Risk in Type 2 Diabetes

Chinese scientists have conducted a comprehensive study on the effectiveness of early insulin therapy for newly diagnosed type 2 diabetes (T2D) patients. The research, spanning 24 years, involved a team of scientists from Anhui Medical University, the University of Science and Technology of China, Southern Medical University, and Peking University. They analyzed data from 5,424 T2D patients across China.

The study revealed a significant benefit of early insulin therapy. Newly diagnosed patients who received this treatment experienced a 31% reduction in stroke risk and a 28% lower risk of hospitalization due to heart failure compared to those who did not receive the therapy.

Furthermore, the study demonstrated that early insulin therapy improved biomarkers associated with low-grade inflammation and endothelial function in newly diagnosed T2D patients. These biomarkers are known indicators of cardiovascular risk. The findings suggest that early insulin therapy may play a crucial role in mitigating cardiovascular complications in T2D patients.

The results of this extensive study provide compelling evidence for adopting early insulin therapy as a first-line treatment option for newly diagnosed T2D patients. The findings were published in the international journal of Signal Transduction and Targeted Therapy in early June.